Literature DB >> 11777958

Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?

Tanina A Cordaro1, Karin E de Visser, Felicia H Tirion, Ton N M Schumacher, Ada M Kruisbeek.   

Abstract

Can self-specific T cells that have escaped intrathymic deletion be exploited to generate antitumor immunity? To determine whether antitumor immunity to a self-Ag for which central tolerance exists can be generated, a mouse model is used in which a fragment of the influenza nucleoprotein (NP) is expressed as a transgene under the control of the H-2K promoter in C57BL/10 mice (B10NP mice). In these mice an oligoclonal population of NP-specific T cells escapes thymic and peripheral deletion and can be activated upon immunization. The main hallmark of these self-specific CD8(+) T cells is diminished avidity for the pertinent MHC/peptide complex. We show in this study that intranasal infection with influenza virus can stimulate low-avidity NP-specific T cells to recognize and destroy NP-expressing microtumors in the lung, but not NP-expressing tumors growing s.c. Only a memory NP-specific CD8(+) T cell response can suppress the growth of an s.c. growing NP-expressing tumor. This delay in tumor growth is associated with a dramatic increase in the number of circulating NP-specific CD8(+) T cells. In addition, cultured memory NP-specific T cells require approximately 100-fold less Ag to induce NP-specific lysis than primary T cells, consistent with the observation that memory T cells have an increased avidity due to affinity maturation. Finally, during an NP-specific memory response, substantial numbers of low-avidity NP-specific T cells can be recovered from s.c. growing tumors. Together, these findings indicate that, when only a low-avidity repertoire is available to generate antitumor immunity, the best strategy may be to enhance memory responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777958     DOI: 10.4049/jimmunol.168.2.651

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

2.  Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Authors:  Jennifer N Uram; Chelsea M Black; Emilee Flynn; Lanqing Huang; Todd D Armstrong; Elizabeth M Jaffee
Journal:  J Immunol       Date:  2011-02-23       Impact factor: 5.422

Review 3.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

4.  Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity.

Authors:  Adam J Adler
Journal:  Curr Immunol Rev       Date:  2005-01-01

5.  CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells.

Authors:  Ziqiang Zhu; Steven M Cuss; Vinod Singh; Devikala Gurusamy; Jennifer L Shoe; Robert Leighty; Vincenzo Bronte; Arthur A Hurwitz
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

6.  Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.

Authors:  Sanjay Sharma; Ana Lucia Dominguez; Soraya Zorro Manrique; Federica Cavallo; Shimon Sakaguchi; Joseph Lustgarten
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 7.  Prospects for immunotherapy of malignant disease.

Authors:  E C Morris; G M Bendle; H J Stauss
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

8.  A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Authors:  Evripidis Lanitis; Jenessa B Smith; Denarda Dangaj; Seleeke Flingai; Mathilde Poussin; Shuwen Xu; Brian J Czerniecki; Yong F Li; Paul F Robbins; Daniel J Powell
Journal:  Hum Gene Ther       Date:  2014-08       Impact factor: 5.695

9.  Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach.

Authors:  Colin Campbell; Ranran Zhang; Jeremy S Haley; Xin Liu; Thomas Loughran; Todd D Schell; Réka Albert; Juilee Thakar
Journal:  Front Physiol       Date:  2011-07-11       Impact factor: 4.566

10.  Avidity maturation of memory CD8 T cells is limited by self-antigen expression.

Authors:  Michael J Turner; Evan R Jellison; Elizabeth G Lingenheld; Lynn Puddington; Leo Lefrançois
Journal:  J Exp Med       Date:  2008-07-14       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.